Long-Term Performance of Prognostic Models for Advanced Renal Cell Carcinoma in the Era of Improved Survival With Immune Checkpoint Inhibitors
This retrospective analysis of the CheckMate-214 trial, in which nivolumab + ipilimumab improved survival versus sunitinib with 48% and 37% of patients, respectively, surviving beyond 5 years, confirmed the strength of the models' prognostication for the early years after first-line sunitinib initiation continuing to stratify three prognostic categories, but also diminished discrimination among long-term survivors and with initiation of nivolumab + ipilimumab. As novel treatments are developed and patients with aRCC live longer, new models to estimate long-term prognosis are needed.
Authors
- David F. McDermott (ORCID: https://orcid.org/0000-0002-2675-5095)
- Meredith M. Regan (ORCID: https://orcid.org/0000-0002-2428-6109)
- Charlene Mantia (ORCID: https://orcid.org/0000-0001-7672-3131)
- Toni K. Choueiri (ORCID: https://orcid.org/0000-0002-9201-3217)
- Michael B. Atkins (ORCID: https://orcid.org/0000-0003-3901-9924)
- Wanling Xie (ORCID: https://orcid.org/0000-0001-5995-8000)
- Opeyemi A. Jegede (ORCID: https://orcid.org/0000-0003-1763-8214)
- Daniel Y.C. Heng
Institutions
- Beth Israel Deaconess Medical Center (US)
- Harvard University (US)
- University of Calgary (CA)
- Georgetown University (US)
- Georgetown University Medical Center (US)
- Dana-Farber Cancer Institute (US)
Publication Details
- Journal
- JCO Oncology Practice
- Published
- 2025-07-14
- DOI
- https://doi.org/10.1200/op-25-00089
- Citations
- 1
- Primary Topic
- Renal cell carcinoma treatment
- Type
- article
- Field-Weighted Citation Impact
- 1.52